Back to resultsIGFBP-3 in Ovarian Cancer Invasion
Primary Purpose
Ovarian Carcinoma
Status
Unknown status
Phase
Not Applicable
Locations
Taiwan
Study Type
Interventional
Intervention
immunohistochemical staining, transfection, invasion assay
Sponsored by
About this trial
This is an interventional diagnostic trial for Ovarian Carcinoma focused on measuring invasion, migration, metastasis, IGFBP-3, transfection, signal transduction.
Eligibility Criteria
Inclusion Criteria: Ovarian Endometrioid Adenocarcinoma Exclusion Criteria: Other types of ovaria epithelial cell carcinoma
Sites / Locations
- National Taiwna University HospitalRecruiting
Outcomes
Primary Outcome Measures
migration, invasion, metastasis
Secondary Outcome Measures
transfection efficiency
Full Information
NCT ID
NCT00154986
First Posted
September 9, 2005
Last Updated
September 9, 2005
Sponsor
National Taiwan University Hospital
1. Study Identification
Unique Protocol Identification Number
NCT00154986
Brief Title
IGFBP-3 in Ovarian Cancer Invasion
Official Title
Study of IGFBP-3 in the Ovarian Carcinoma Cell Invasion
Study Type
Interventional
2. Study Status
Record Verification Date
April 2004
Overall Recruitment Status
Unknown status
Study Start Date
August 2004 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
July 2005 (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
National Taiwan University Hospital
4. Oversight
5. Study Description
Brief Summary
An ovarian cancer cell line (OVTW-59) derived from an ovarian endometrioid carcinoma was established and its sublines, labeled as P0, P1, P2, P3, and P4 with increasing invasion abilities were selected from transwell invasion chambers.Using cDNA microarray and verified with quantitative reverse-transcriptase polymerase chain reaction, we have identified IGFBP-3 as an invasion-suppressor gene. We plan to study the role of IGFBP-3 in ovarian cancer invasion.
Detailed Description
We have successfully established an ovarian cancer cell line (OVTW-59), which was derived from an ovarian endometrioid carcinoma. Its sublines, labeled as P0, P1, P2, P3, and P4 with increasing invasion abilities, were selected from transwell invasion chambers, where P0 represented the original cell line at 100th passage. By using cDNA microarray and verified with quantitative reverse-transcriptase polymerase chain reaction, we have identified the differentially gene expression profiles of these OVTW-59 series cell lines in order to identify the invasion related suppressor and oncogenes from ovarian carcinoma. From these genes, we selected insulin-like growth factor binding protein (IGFBP)-3, which is a suppressor gene, and found it lower expressed in higher-grade tumors and correlated with poor patient survival. In vitro, we found IGFBP-3 related to the inhibition of cancer cell migration. In this study, we plan to setup stable transfected IGFBP-3 cell lines in P0 and P4, and study the relationship among IGFBP-3, metalloproteinase-2 (our previous studies which verified its relationship with tumor invasiveness) and insulin-like growth factor (IGF)-1. We would study the changes in cytoskeletal structures and the known functions of anti-proliferation and apoptosis in IGFBP-3. Furthermore, we would like to investigate the mechanism of IGFBP-3 in the inhibition of invasion/migration of ovarian carcinoma, either signaling through MAPK or PI3K/AKT pathways. Finally, through xenograft, we plan to study for the possible application of IGFBP-3 in ovarian cancer therapy.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ovarian Carcinoma
Keywords
invasion, migration, metastasis, IGFBP-3, transfection, signal transduction.
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
Single
Allocation
Non-Randomized
Enrollment
30 (false)
8. Arms, Groups, and Interventions
Intervention Type
Procedure
Intervention Name(s)
immunohistochemical staining, transfection, invasion assay
Primary Outcome Measure Information:
Title
migration, invasion, metastasis
Secondary Outcome Measure Information:
Title
transfection efficiency
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Ovarian Endometrioid Adenocarcinoma
Exclusion Criteria:
Other types of ovaria epithelial cell carcinoma
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Torng Pao-Ling, MD, PhD
Phone
886223123456
Ext
7039
Email
pltorng@ha.mc.ntu.edu.tw
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Torng Pao-Ling, MD, PhD
Organizational Affiliation
Department of Obsteteric and Gynecology, National Tiawan University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
National Taiwna University Hospital
City
Taipei
ZIP/Postal Code
10020
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Torng Pao-Ling, MD, PhD
Phone
886223123456
Ext
7039
Email
pltorng@ha.mc.ntu.edu.tw
First Name & Middle Initial & Last Name & Degree
Torng Pao-Ling, ME, PhD
12. IPD Sharing Statement
Learn more about this trial
IGFBP-3 in Ovarian Cancer Invasion
We'll reach out to this number within 24 hrs